A randomized phase II study comparing consolidation with a single dose of Y-90 ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results
| العنوان: | A randomized phase II study comparing consolidation with a single dose of Y-90 ibritumomab tiuxetan vs. maintenance with rituximab for two years in patients with newly diagnosed follicular lymphoma responding to R-CHOP. Long-term follow-up results |
|---|---|
| المؤلفون: | Lopez-Guillermo, Armando, Canales, Miguel Angel, Dlouhy, Ivan, Mercadal, Santiago, Briones, Javier, Martin Garcia-Sancho, Alejandro, Sancho, Juan Manuel, Maria Moraleda, Jose, Terol, Maria Jose, Salar, Antonio, Palomera, Luis, Gardella, Santiago, Jarque, Isidro, Ferrer, Secundino, Bargay, Joan, Lopez, Andres, Panizo, Carlos, Muntañola, Anna, Montalban, Carlos, Conde, Eulogio, Hernandez, Miguel T., Soler, Alfons, Garcia Marco, Jose A., Deben, Guillermo, Marin, Julian, Tomas, Jose Francisco |
| المصدر: | LEUKEMIA & LYMPHOMA r-FISABIO. Repositorio Institucional de Producción Científica instname r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol Leukemia & lymphoma r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe |
| بيانات النشر: | TAYLOR & FRANCIS LTD, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | 90Y ibritumomab tiuxetan, 90Y ibritumomab tiuxetan, Follicular lymphoma, maintenance, Follicular lymphoma, maintenance |
| الوصف: | This is a randomized phase-2 trial aimed to compare consolidation vs. maintenance in untreated patients with follicular lymphoma (FL) responding to induction. 146 patients were enrolled from 25 Spanish institutions (ZAR2007; ClinicalTrials.gov #NCT00662948). Patients in PR or CR/CR[u] after R-CHOP were randomized 1:1 to Y-90-ibritumomab-tiuxetan 0.4 mCi/kg (arm A) vs. rituximab 375 mg/m(2) every 8 weeks for 2 years (arm B). After a median follow-up of 10.55 years, 53 patients eventually progressed with a 10-year PFS of 50% vs. 56% for patients in arm A and B, respectively (HR = 1.42; p > 0.1). No significant differences were seen in OS (10-year OS 78% vs. 84.5%; HR = 1.39, p > .1). Patients receiving Y-90-ibritumomab-tiuxetan showed higher incidence of second neoplasms than those in arm B (10-year cumulative incidence 18.5 vs. 2%, respectively; p = .038). In conclusion, in FL patients responding to R-CHOP, no significant differences were found between consolidation and maintenance, although with higher late toxicity for consolidation. |
| تدمد: | 1042-8194 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::b64a3d520daac0111273a2996543fd52Test https://fundanet.fisabio.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=10714Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.dedup.wf.001..b64a3d520daac0111273a2996543fd52 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 10428194 |
|---|